Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Treasury Shares: 2014-2025

Historic Treasury Shares for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Sep 2025 value amounting to $1.1 million.

  • Viridian Therapeutics, Inc.\DE's Treasury Shares rose 111.93% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 111.93%. This contributed to the annual value of $314,075 for FY2024, which is 60.98% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Treasury Shares stood at $1.1 million, which was down 1.61% from $1.1 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Treasury Shares' 5-year high stood at $1.1 million during Q1 2025, with a 5-year trough of $314,075 in Q4 2024.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Treasury Shares value was $589,696 (recorded in 2024), while the average stood at $663,088.
  • Its Treasury Shares has fluctuated over the past 5 years, first tumbled by 60.98% in 2024, then soared by 111.93% in 2025.
  • Viridian Therapeutics, Inc.\DE's Treasury Shares (Quarterly) stood at $804,947 in 2023, then slumped by 60.98% to $314,075 in 2024, then skyrocketed by 111.93% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.